NAFLD also reduced by 78% (p < 0.001) and 62% (p < 0.05) hepatic mRNA expression of Ldlr and Lrp1, respectively, with no change in Lsr expression (Figure 5C). The gene discussed is LRP1; the disease is metabolic dysfunction-associated steatotic liver disease.